Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Core Insights - Veru Inc. is a late clinical stage biopharmaceutical company focused on innovative medicines for cardiometabolic and inflammatory diseases [2][10] - The company will present at the 2nd Annual GLP-1-Based Therapeutics Summit from April 29 to May 1, 2025, in Boston, Massachusetts [1] Enobosarm Development - Enobosarm is a selective androgen receptor modulator (SARM) aimed at enhancing weight reduction by GLP-1 RA drugs, focusing on fat loss while preserving lean mass [2][3] - The Phase 2b QUALITY clinical trial demonstrated a 71% relative reduction in lean mass loss for patients receiving enobosarm with semaglutide compared to placebo [4] - The enobosarm 3mg + semaglutide group showed a >99% mean relative reduction in lean mass loss, indicating significant efficacy [4] Clinical Trial Results - Secondary endpoints indicated that enobosarm + semaglutide resulted in a 46% greater relative loss of fat mass compared to placebo + semaglutide [5] - The median total body weight loss in the placebo + semaglutide group was 32% lean mass and 68% fat loss, while the enobosarm + semaglutide group had 9.4% lean mass and 90.6% fat loss, showing a shift towards greater fat loss [5] - The study found that 42.6% of patients on placebo + semaglutide experienced a ≥10% decline in stair climb power, while the enobosarm + semaglutide group had a 54.4% reduction in this decline [6][7] Safety and Future Studies - Safety data from the Phase 2b QUALITY study remains blinded, with an unblinded complete safety set expected after the ongoing extension study [8] - The Phase 2b extension trial will evaluate enobosarm's ability to maintain muscle and prevent fat regain after discontinuing semaglutide, with topline results expected in Q2 2025 [9] Sabizabulin Development - Veru is exploring sabizabulin for treating inflammation in atherosclerotic cardiovascular disease, addressing a significant unmet medical need [10][13] - Sabizabulin has shown broad anti-inflammatory activity in previous studies and may be combined with statin therapy for enhanced efficacy [12] - The company plans to submit a new IND for sabizabulin in the first half of 2026, with ongoing preclinical studies [14]